Updates are available Correction dated 2025-02-03

Article History

Received: 8 July 2024

Accepted: 20 September 2024

First Online: 6 November 2024

Change Date: 3 February 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s44325-025-00045-x

Competing interests

: G.B. has received personal fees from Abbott, AstraZeneca, Boehringer-Ingelheim and Novartis, outside the submitted work. L.M. has received personal fees from AstraZeneca and Vifor outside the submitted work. N.G. has received personal fees from AstraZeneca, Bayer, Boehringer, Novartis and Vifor outside the submitted work. I.L.P. has no conflicts of interest related to the submitted work. M.C.P. has no conflicts of interest related to the submitted work. K.D. has no conflicts of interest related to the submitted work. A.M. has received grants from Roche Diagnostics, Abbott Laboratories, 4TEEN4, and Windtree Therapeutics; honoraria for lectures from Roche Diagnostics, Bayer, and MSD; is a consultant for Corteria Pharmaceuticals, S-form Pharma, FIRE-1, Implicity, 4TEEN4, and Adrenomed; and is coinventor of a patent on combination therapy for patients having acute or persistent dyspnoea outside the submitted work. L.A. has no conflicts of interest related to the submitted work. J.B. has received personal fees from Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll outside the submitted work. F.Z. has received personal fees from 89Bio, Abbott, Acceleron, Applied Therapeutics,Bayer, Betagenon, Boehringer, BMS, CVRx, Cambrian, Cardior, Cereno pharmaceutical,Cellprothera, CEVA, Inventiva, KBP, Merck, NovoNordisk, Owkin, Otsuka, Roche Diagnostics,Northsea, USa2, having stock options at G3Pharmaceutical and equities at Cereno,Cardiorenal, Eshmoun Clinical research and being the founder of Cardiovascular ClinicalTrialists outside the submitted work. H.V.S. receives research funding from Canadian Institutes of Health Research and Medtronic; and education program funding from Boehringer Ingelheim and Novartis.